<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05621590</url>
  </required_header>
  <id_info>
    <org_study_id>IR.SBMU.RETECH.REC.1400.510</org_study_id>
    <nct_id>NCT05621590</nct_id>
  </id_info>
  <brief_title>MLC901 in Hypoxic-ischemic Brain Injury Patients; A Double-blind, Randomized Placebo-controlled Trial</brief_title>
  <official_title>MLC901 in Hypoxic-ischemic Brain Injury Patients; A Double-blind, Randomized Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a randomized, placebo-controlled trial, 35 patients with HIBI were randomly designated to&#xD;
      receive either MLC901 or placebo capsules over six months.&#xD;
&#xD;
      We evaluated patients in two groups by modified Rankin Scale (mRS) and Glasgow outcome scale&#xD;
      (GOS) to examine their state of disability and recovery&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 10, 2020</start_date>
  <completion_date type="Actual">August 12, 2022</completion_date>
  <primary_completion_date type="Actual">August 12, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neurofunctional outcome using Glasgow Outcome Scale (GOS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>neurofunctional outcome using modified Rankin Scale (mRS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Hypoxic Ischaemic Encephalopathy Due to Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>mlc-901 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MLC 901</intervention_name>
    <description>MLC901, also known as NeuroAiDII, is a capsule form of drug which should be taken orally and combines nine herbal components</description>
    <arm_group_label>mlc-901 group</arm_group_label>
    <other_name>Nueroaid II</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo capsules filled with stevia sweetened powder</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  an initial cardiac arrest leading to coma, successful return of spontaneous&#xD;
             circulation, and persistent coma after the return of spontaneous circulation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy, cardiogenic shock (systolic blood pressure less than 90 mm Hg despite&#xD;
             epinephrine infusion), possible causes of coma other than cardiac arrest (drug&#xD;
             overdose, head trauma, or cerebrovascular accident), an underlying background of known&#xD;
             acute or chronic disease including renal failure, liver or pulmonary disorders,&#xD;
             previous stroke, dementia, and brain injury.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shahid Beheshti University of Medical Sciences, Shohada Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <reference>
    <citation>Pakdaman H, Amini Harandi A, Gharagozli K, Abbasi M, Ghaffarpour M, Ashrafi F, Delavar Kasmaei H, Amini Harandi A. MLC601 in vascular dementia: an efficacy and safety pilot study. Neuropsychiatr Dis Treat. 2017 Oct 5;13:2551-2557. doi: 10.2147/NDT.S145047. eCollection 2017.</citation>
    <PMID>29042785</PMID>
  </reference>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 11, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2022</study_first_posted>
  <last_update_submitted>November 17, 2022</last_update_submitted>
  <last_update_submitted_qc>November 17, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Ali Amini Harandi</investigator_full_name>
    <investigator_title>associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Hypoxia-Ischemia, Brain</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

